Precision BioSciences Inc (DTIL)

[rtrstock]

Cathie Martin, has gained an approval for Purple Tomatoes in the U.S., antioxidant rich. She's apparently a brilliant genetic scientist with Norfolk Plant Scientists, now I know Precision Biosciences has billions in funding from Cargill, in consideration of plant genetics, I'd love to see a collaboration benefiting all. Congratulations to Cathie and her team, an excellent U.S.D.A. Approval, tomatoes expected to be distributed as early as 2023.

https://www.msn.com/en-us/foodanddrink/foodnews/usda-approves-genetically-modified-antioxidant-rich-purple-tomato/ar-AA12mnNy?li=BBnb2gh

[swampboots]

DTIL: (1.50's or lower target buying price) I am a sometimes investor as stock uses its shareholders to sponsor its expensive goals, But recent multiple handshakes with top tiered drug houses, insider buying, and recent share offering swallowed into current share price offered (to me) better safety than peers which lacked such a recent trifecta.
Highly notable to me and more comforting as an investor are the almost daily discoveries of new mechanisms which may introduce new solutions that for example may block or turn on or off influences which affect even approved CART-T safety and effectiveness. In my opinion, this implies that all Cart-T platforms have available outsource able safety nets to in theory most likely improve their platform in a significant profitable way, and made available to patients as long as the cost of their treatment has a market for their improved delivery system.
https://medicalxpress.com/news/2022-09-immune-cells-cancer.html?utm_source=
https://www.sciencedaily.com/releases/2022/09/220909191820.htm


(if a problem with the links) a copy and paste on Goggle did the trick for me.

[jondoeuk]

New preclinical data https://www.nature.com/articles/s41417-022-00518-6

[jondoeuk]

(OT) Two new papers https://medicalxpress.com/news/2022-08-technology-success-car-t-cell-immunotherapy.html https://www.businesswire.com/news/home/20220828005032/en/New-Data-in-Nature-Medicine-Suggest-Pre-Treatment-Tumor-Microenvironment-Can-Impact-Response-for-CAR-T-Cell-Therapy-in-Patients-with-Large-B-Cell-Lymphoma

[jondoeuk]

The company's long-term goal is for PBCAR19B to displace auto products. The program was strategically paused in Q1 to implement an optimised manufacturing process, which was to increase a T-cell memory subset with stem cell-like properties. Data on some patients treated at DL2 (540M cells) with the new lots, as well as those from DL1 (270M cells) could either be presented at ASH or an investor event. However, it won't be until next year until there will be a longer follow-up for durability. So until then we won't have an idea if it really could do what they hope.

Moving to PBCAR269A with nirogacestat, I have mixed views about this program. I know the CAR can't target cells with low BCMA levels (which is why they added niro). Also, the space is becoming more crowed, and many are moving toward dual targeted CARs. If they would do the same, but target other antigens that aren't being pursued by many, that could be a better long-term strategy.

[jondoeuk]

Thanks for the list. It is not long compared to the one for CD19.

No, but in the trial, patients receive two cycles of LD chemo, followed by AFM13 pre-complexed cbNKs and three weekly IV infusions of AFM13, so slightly more involved than CAR-T.

I am trying to figure out how innate engagers affect TAMs thru CD16.

The innate cell engagers bind to the CD16a receptor on NK cells and macrophages https://www.tandfonline.com/doi/full/10.1080/19420862.2019.1616506 https://www.sciencedirect.com/science/article/pii/S0006497119371605

Also, for a number of the trials they are adding either an anti-PD(L)-1 or pre-complexed cbNKs as well.

[swampboots]

I think it is an interesting attempt to place DTIL's CART-T platform in comparison to its "peers".
but a highly impossible task without sorting out the 1000's of new studies each month in this field. I am relying on insider buying, fruitful handshakes with some big drug Companies, the Co's cash burn position, as well as the shortness of time since last pipe dilution.
With no scientific credentials I read dozens of new studies a day in the cancer field, and
try to imitate a journalist in my digestions of the information relayed as tidy summaries.
And weekly for sure new tweaks to the Cart-T arena are proposed, some to reduce costs, improve accuracy, limit mis-maufacturing mistakes in the expensive customizing of their applications, as microscopic contamination difficult to contain or measure.. In addition to toying with new discovered proteins which must be suppressed, added or mingled to make the CART-T platform more effective. It is a moving target where one simple new discovery can weigh heavily on the ultimate effectiveness toward endpoint mastery.......To repeat I have to assume insiders and big drug Co.'s offering some of their risk , favors the odds to me by relying on better eyes concluding more probable credibility, as their surveilance is closer to the microscope sorting out the unresolved challenges I am not in the loop to know..

[NY1972]

Thanks for the list. It is not long compared to the one for CD19. I am trying to figure out how innate engagers affect TAMs thru CD16.

[jondoeuk]

It faces competition from other cell therapies. I know TT11 (an auto anti-CD30 CAR-T) is already in a pivotal trial for late stage cHL [1], late stage CD30+ NHL, as well as a potential second line therapy (plus four doses of Opdivo) in cHL.

TT11X (healthy donor EBVSTs, with the same CAR) is also being tested in CD30+ lymphomas [2]. NTLA is also moving forward a healthy donor anti-CD30 CAR-T [3]. Another potential benefit is addition engineering. In this, they added a chemokine receptor [4].

Refs:
1 https://www.globenewswire.com/en/news-release/2021/12/13/2351226/0/en/Tessa-Therapeutics-Announces-Positive-Data-from-Phase-2-Trial-of-Autologous-CD30-CAR-T-Therapy-TT11-in-Relapsed-or-Refractory-Classical-Hodgkin-Lymphoma-at-2021-ASH-Annual-Meeting.html
2 https://www.globenewswire.com/en/news-release/2021/12/11/2350320/0/en/Tessa-Therapeutics-Showcases-Positive-Clinical-Data-from-Phase-1-Study-of-Off-the-Shelf-CD30-Cell-Therapy-at-2021-Annual-Meeting-of-American-Society-of-Hematology-ASH.html
3 https://www.globenewswire.com/en/news-release/2022/05/02/2433370/0/en/Intellia-Therapeutics-Presents-Preclinical-Data-Demonstrating-Advancements-in-its-CRISPR-Engineered-Allogeneic-Platform-at-the-2022-Keystone-Symposia-s-Precision-Genome-Engineering.html
4 https://ashpublications.org/blood/article/138/Supplement%201/742/480022/CD30-Directed-CAR-T-Cells-Co-Expressing-CCR4-in

[carusso]

New to this board. Could anyone tell me the main reasons for the decline in share price here since last Sept/Oct highs?

[NY1972]

cbNK cells pre-complexed with engager is safe and CAR like.

As of October 31, 2021, a total of 18 patients with CD30-positive relapsed or refractory Hodgkin and non-Hodgkin lymphomas (16 and 2 patients, respectively) were treated with the novel combination of cbNK cells pre-complexed with AFM13.
As of the cutoff date, 16 of 18 patients had achieved an objective response to the treatment according to investigator assessment, with seven complete responses (CR) and nine partial responses.
100% objective response rate (ORR) was observed with a 42% CR rate in 12 patients with Hodgkin Lymphoma, after the 1st of 2 planned cycles at the recommended phase 2 dose of 108 cbNK cells/kg pre-complexed with AFM13.
No cases of serious adverse events such as cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease were observed.
Treatment was well tolerated with five reported cases of transient infusion related reactions after the monotherapy infusions of AFM13.

[jondoeuk]

The poster is now up https://precisionbiosciences.com/wp-content/uploads/2022/07/Pires-M-Allogeneic-CAR-T-Cells-with-Deoxycytidine-Kinase-Knockdown.-SITC.-2021..pdf

Others, include knockdown of CD319 (reduces or prevents fratricide of CAR+ cells), TGFRB2 (less susceptible to immunosuppression by transforming growth factor beta), CBL-B (less susceptible to suppression of TCR and PD-L1 signaling), CD52 (less susceptible to CD52 antibody induced death) and/or the glucocorticoid receptor (less susceptible to glucocorticoids).

Hopefully, they will start to incorporate these and build a 'library' of additional shRNAs targeting more genes, such as PD-1 https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(21)00498-6 https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7522 https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e14514

[swampboots]

DTIL 2.15 -1.61 I am all ears.

[rtrstock]

https://www.defenseworld.net/2022/08/15/sg-americas-securities-llc-buys-shares-of-10821-precision-biosciences-inc-nasdaqdtil.html

Hedge Funds and other institutional investors buying Precision Biosciences stock.

[rtrstock]

Can't believe there isn't more talk on InvestorsHub about Precision Biosciences after Friday, +23% hope this continues up, I really need it.

[swampboots]

Just put sickle cell drug into google search and mystery will be solved, and if you are displeased with me pumping DTIL all along, I want to know about it!.

[carusso]

And what is YOUR first language?

Such interesting people here...

[swampboots]

DTIL 1.90 as mist of sickle cell throw by a big boy drug house, of billions into
some platform drug.

[swampboots]

DTIL Goldman Sachs lowers target to $2, I need below 1.50 to restart safe.

[swampboots]

DTIL sold all into .45 loss as expected (above 1.70's) , but boring wait till data, so want lower to get back all I sold.

[rtrstock]

https://www.defenseworld.net/2022/08/06/precision-biosciences-dtil-set-to-announce-quarterly-earnings-on-monday.html

Quarterly Earnings Monday

Waiting for much much higher...like this alot

[swampboots]

DTIL 1.75 Monday it will command more vol.

[swampboots]

DTIL 1.60 , staying in 50 day channel, want some morei 1.50's.

[swampboots]

DTIL 1.70 sold 1/2 as went down more than went up o these yoyo moves, so equals same if it goes dow for me before it makes its move.

[swampboots]

DTIL 1.70 OK its ready to do the 2!

[swampboots]

DTIL 1.60 now its read with technical backing.

[swampboots]

DTIL 1.52 small creep to highest share hold, waiting for spike but want to duck any bad earnings surprises next week.

[swampboots]

DTIL 1.42 lowest able but sold some 1.53..got killed yesterday buying low and not being able to sell to buy AMTD, nuts!

[swampboots]

DTIL: while waiting of excelled explanation:
https://www.healio.com/news/hematology-oncology/20210810/onestep-geneediting-technique-opens-door-to-safe-effective-offtheshelf-car-t-cells#:~:text=ARCUS%20is%20a%20proprietary%20platform,of%20design%20or%20fast%20turnaround

[swampboots]

DTIL 1.50 rebuy, want 1.40's for end play.

[swampboots]

DTIL :
Soon-Shiong CEO of Nanthealth became a billionaire after selling two drug companies: APP Pharmaceuticals and Abraxis BioScience. He sold APP to Fresenius Medical Care for $4.6 billion in 2008, and Abraxis to Celgene for $2.8 billion in 2010. He owns the Los Angeles Times and a 4.5% stake in the Lakers professional basketball team.


See DTIL sued Soon-Shiong in 2017, wonder what happened to that suit?
https://casetext.com/case/feldman-ex-rel-precision-biologics-inc-v-patrick-soon-shiong-charles-kim-christian-zapf-nantcell-inc

[swampboots]

Emerging new findings on ways to increase the immune response can only ( I assume) benefit CART-T outfits like DTIL.
https://medicalxpress.com/news/2022-07-immune-response-cancer.html

[swampboots]

DTIL: 1.57-1.58 rebuys.

[rtrstock]

Confident here.

[swampboots]

If we all knew what could not stay down we would own a mint.

[rtrstock]

I don't see how this can stay down, too many multi billion dollar companies involved, Novartis! Cargill!

[swampboots]

DTYIL 1.60 ok 1/2 way there.

[swampboots]

I am looking for 1.50 before 2, as I assume it wants to slide but zoom on a nice PR? I am not betting on any riches from DTIL, just dreaming of that prospect.

[rtrstock]

Will this stock split? Noticed it's never split before, no dividend, company should grow, in my opinion, shouldn't this split eventually?

Also, I chose the lend out shares option on robinhood, hope they lend my shares, for passive income, then will reinvest gains back into precision.

I hope this is like buying one of those companies that you hear about people getting rich from, buying at the near inception of the company. Really excited.

[swampboots]

No idea but thought right now should be $5.....to many homespun marks checked.......insider buying, royalty deals with 70K left to settle, cash to 2024, recent dilution offering.they seem vaccinated for $5 now?

[swampboots]

No idea but thought right now should be $5.....to many homespun marks checked.......insider buying, royalty deals with 70K left to settle, cash to 2024, recent dilution offering.they seem vaccinated for $5 now?

[rtrstock]

What could the pps be longterm? They have deals with Cargill, and think crispr is trading at 80.00, what's the potential here?
Zacks has a buy rating, and some predictions put this at a next 52wk high of 14.00-20.00
These seem like good prices now.

This is trading on Nasdaq afterall, plenty of Nasdaq symbols go up.

[swampboots]

DTIL 1.67 should be $5+ , technical chart destruction dictating share price short term.

[swampboots]

DTIL 1.53:
"Live In Play®
Updated: 18-Jul-22 07:37 ET
DTIL: Precision BioSciences received the $50 mln upfront cash payment from Novartis (NVS) under the Collaboration and License Agreement on July 12 (1.42)
The Company expects that as of July 12, 2022, this cash payment, together with its existing cash and cash equivalents, expected operational receipts, and available credit, will be sufficient to fund its operating expenses and capital expenditure to year-end 2024.
Although it has not finalized its full financial results for the quarter ended June 30, 2022, the Company expects to report that it had approximately $184 million in cash and cash equivalents as of June 30, 2022 including receipts of $25 million from Novartis' equity investment in the Company and the June 2022 underwritten offering of the Company's common stock. This amount does not include $50 million in cash received from Novartis subsequent to June 30, 2022."

[swampboots]

DTIL 1.41 sold many gems to add here, close to offering price.!

[jondoeuk]

It should. Simultaneous quad editing of T-cells using BEAM's base editor (CBE; C-to-T) resulted in no detected aberrant karyotypes compared to Cas9* edited cells with the same four gRNAs producing twenty-two aberrant karyotypes (100 cells evaluated).

Based edited cells (again, BEAM's own data) decreased expression of the four targeted genes (efficacy of 94-98% at each target gene), but had only minimal effect on other genes, while Cas9* induced differential expression of over 1,500 genes, including the p53 pathway.

* Keep in mind that CRSP and others continue to enhance their Cas9 systems through protein engineering, as well as identifying optimal gRNAs (both formats and sequences). So an apples to pears comparison.

[swampboots]

DTIL 1.76.

[swampboots]

DTIL 1.67 , been a few days since this level?

[NY1972]

Base editing reminds me of vaccine boosters. It can be done safely every few months with no side effects according to the science gods at NIH. Really?

[swampboots]

"the unintended events" are being reduced each day by
computational and experimental methods that are bringing researchers closer to their goal of revealing exactly where in a cell or tissue each gene is expressed.